{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:45:20Z","timestamp":1794923120996,"version":"4.9.1"},"reference-count":25,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008366","name":"Danmarks Lungeforening","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008366","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Danish Regions Medicines Fund"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2024,5,14]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-interleukin (IL)-5 biologics effectively reduce exacerbations and the need for maintenance oral corticosteroids (mOCS) in severe eosinophilic asthma. However, it is unknown how long anti-IL-5 treatment should be continued. Data from clinical trials indicate a gradual but variable loss of control after treatment cessation. In this pilot study of titration, we evaluated a dose-titration algorithm in patients who had achieved clinical control on an anti-IL-5 biologic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label randomised controlled trial conducted over 52\u2005weeks, patients with clinical control (no exacerbations or mOCS) on anti-IL-5 treatment were randomised to continue with unchanged intervals or have dosing intervals adjusted according to a titration algorithm that gradually extended dosing intervals and reduced them again at signs of loss of disease control. The OPTIMAL algorithm was designed to down-titrate dosing until signs of loss of control, to enable assessment of the longest dosing interval possible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 73 patients enrolled, 37 patients were randomised to the OPTIMAL titration arm; 78% of patients tolerated down-titration of treatment. Compared to the control arm, the OPTIMAL arm tended to have more exacerbations during the study (32%\n                      <jats:italic>versus<\/jats:italic>\n                      17%; p=0.13). There were no severe adverse events related to titration, and lung function and symptoms scores remained stable and comparable in both study arms throughout.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study serves as a proof of concept for titration of anti-IL-5 biologics in patients with severe asthma with clinical control on treatment, and the OPTIMAL algorithm provides a potential framework for individualising dosing intervals in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.00404-2024","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T11:55:13Z","timestamp":1717674913000},"page":"2400404","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study)"],"prefix":"10.1183","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4954-0863","authenticated-orcid":false,"given":"Marianne Baastrup","family":"Soendergaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sofie","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Makowska","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Lock-Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-3463","authenticated-orcid":false,"given":"Ole","family":"Hilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9550-6703","authenticated-orcid":false,"given":"Susanne","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"von Bulow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Porsbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"2024102103305297000_64.2.2400404.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805435"},{"key":"2024102103305297000_64.2.2400404.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"2024102103305297000_64.2.2400404.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2024102103305297000_64.2.2400404.4","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"2024102103305297000_64.2.2400404.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2024102103305297000_64.2.2400404.6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024102103305297000_64.2.2400404.7","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00238-2022"},{"key":"2024102103305297000_64.2.2400404.8","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.jaip.2023.05.025","article-title":"Long-term real-world outcomes of mepolizumab and benralizumab among biologic-naive patients with severe eosinophilic asthma: experience of 3","volume":"11","author":"Fyles","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102103305297000_64.2.2400404.9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/02770903.2022.2036754","article-title":"Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience","volume":"60","author":"Matucci","year":"2023","journal-title":"J Asthma"},{"key":"2024102103305297000_64.2.2400404.10","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/JAA.S391807","article-title":"Long-term efficacy and clinical remission after benralizumab treatment in patients with severe eosinophilic asthma: a retrospective study","volume":"15","author":"Numata","year":"2022","journal-title":"J Asthma Allergy"},{"key":"2024102103305297000_64.2.2400404.11","doi-asserted-by":"crossref","first-page":"106260","DOI":"10.1016\/j.rmed.2020.106260","article-title":"Oral corticosteroid sparing effects of anti-IL5\/anti-IL5 receptor treatment after 2\u2005years of treatment","volume":"176","author":"Bjerrum","year":"2021","journal-title":"Respir Med"},{"key":"2024102103305297000_64.2.2400404.12","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti-IL-5 biologics in severe asthma \u2013 a real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102103305297000_64.2.2400404.13","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin Ther"},{"key":"2024102103305297000_64.2.2400404.14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3390\/jcm12030985","article-title":"Effectiveness of benralizumab in OCS-dependent severe asthma: the impact of 2\u2005years of therapy in a real-life setting","volume":"12","author":"Vitale","year":"2023","journal-title":"J Clin Med"},{"key":"2024102103305297000_64.2.2400404.15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12931-023-02439-w","article-title":"Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study","volume":"24","author":"Vultaggio","year":"2023","journal-title":"Respir Res"},{"key":"2024102103305297000_64.2.2400404.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.11.026"},{"key":"2024102103305297000_64.2.2400404.17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13223-019-0348-z","article-title":"Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial","volume":"15","author":"Ortega","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2024102103305297000_64.2.2400404.18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00396-2021"},{"key":"2024102103305297000_64.2.2400404.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2024102103305297000_64.2.2400404.20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/rheumatology\/key244","article-title":"Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care \u2013 2-year outcomes and predictors","volume":"58","author":"Brahe","year":"2019","journal-title":"Rheumatology"},{"key":"2024102103305297000_64.2.2400404.21","doi-asserted-by":"crossref","first-page":"100703","DOI":"10.1016\/j.waojou.2022.100703","article-title":"Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma","volume":"15","author":"B\u00f6lke","year":"2022","journal-title":"World Allergy Organ J"},{"key":"2024102103305297000_64.2.2400404.22","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2024102103305297000_64.2.2400404.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"2024102103305297000_64.2.2400404.24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40629-018-0087-6","article-title":"Comparison of extended intervals and dose reduction of omalizumab for asthma control","volume":"28","author":"B\u00f6lke","year":"2019","journal-title":"Allergo J Int"},{"key":"2024102103305297000_64.2.2400404.25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bcp.13453","article-title":"A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients","volume":"84","author":"Domingo","year":"2018","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00404-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:20:54Z","timestamp":1740363654000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00404-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,8,22]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1183\/13993003.00404-2024"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00404-2024","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1183\/13993003.00404-2024.supp1","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1183\/13993003.00404-2024.shareable1","asserted-by":"subject"}]},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]}}}